Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunovant (IMVT) Total Liabilities (2018 - 2026)

Immunovant filings provide 8 years of Total Liabilities readings, the most recent being $66.3 million for Q4 2025.

  • Quarterly Total Liabilities fell 3.01% to $66.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $66.3 million through Dec 2025, down 3.01% year-over-year, with the annual reading at $68.8 million for FY2025, 41.49% up from the prior year.
  • Total Liabilities hit $66.3 million in Q4 2025 for Immunovant, up from $63.3 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $68.8 million in Q1 2025 and bottomed at $21.0 million in Q1 2021.
  • Average Total Liabilities over 5 years is $45.0 million, with a median of $44.2 million recorded in 2023.
  • Peak annual rise in Total Liabilities hit 131.72% in 2023, while the deepest fall reached 22.77% in 2023.
  • Immunovant's Total Liabilities stood at $38.0 million in 2021, then increased by 9.28% to $41.6 million in 2022, then fell by 22.77% to $32.1 million in 2023, then skyrocketed by 112.81% to $68.3 million in 2024, then dropped by 3.01% to $66.3 million in 2025.
  • Per Business Quant, the three most recent readings for IMVT's Total Liabilities are $66.3 million (Q4 2025), $63.3 million (Q3 2025), and $52.9 million (Q2 2025).